Navigation Links
AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
Date:10/24/2008

QUEBEC CITY, Oct. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it received a letter from the Nasdaq Stock Market, notifying AEterna Zentaris that during the 30 consecutive business days prior to October 16, 2008, the bid price of the Company's common shares had closed below the US$1.00 minimum bid per share required for continued inclusion on the Nasdaq Global Market under Marketplace Rule 4450(a)(5). However, the letter states that given the current extraordinary market conditions, Nasdaq has determined to suspend enforcement of the bid price and market value of publicly held shares requirements through Friday, January 16, 2009. In that regard, the letter states that on October 16, 2008, Nasdaq filed an immediately effective rule change with the Securities and Exchange Commission to implement the suspension. According to Nasdaq, these rules will be reinstated on Monday, January 19, 2009 and the first relevant trade date will be Tuesday, January 20, 2009.

Therefore, following the reinstatement of these rules, and in accordance with Marketplace Rule 4450(e)(2), AEterna Zentaris will be provided 180 calendar days from Tuesday, January 20, 2009, or until July 20, 2009, to regain compliance with the US$1.00 minimum bid per share under Marketplace Rule 4450(a)(5). If, at any time before July 20, 2009, including during the suspension period, the bid price of the Company's common shares closes at US$1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will provide written notification that AEterna Zentaris has achieved compliance with Marketplace Rule 4450(a)(5).

If the Company is unsuccessful in meeting the minimum bid requirement by July 20, 2009, Nasdaq will provide notice to AEterna Zentaris that its common shares will be delisted from the Nasdaq Global Market. If the Company receives a delisting notification, it may appeal to the Listing Qualifications Panel or apply to transfer its common shares to the Nasdaq Capital Market if AEterna Zentaris satisfies all criteria for initial listing on the Nasdaq Capital Market in accordance with Marketplace Rule 4310(c), other than compliance with the minimum closing bid price requirement. If the application to the Nasdaq Capital Market is approved, then the Company will have an additional 180-day compliance period in order to regain compliance with the minimum bid price requirement while listed on the Nasdaq Capital Market.

The Nasdaq letter has no immediate effect on the listing of the Company's common shares. On October 16, 2008, the closing price of the Company's common shares was US$0.60 per share.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
5. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
6. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
7. AEterna Zentaris Sells Quebec City Building for $7.1 million
8. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
9. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
10. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
11. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call ... complex biological network, a depiction of a system of linkages and connections so ... PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) and director ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
Breaking Biology Technology:
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):